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Abstract: With the introduction of new genetic techniques such as genome-wide array 
comparative genomic hybridization, studies on the putative genetic etiology of schizophrenia 
have focused on the detection of copy number variants (CNVs), ie, microdeletions and/or 
microduplications, that are estimated to be present in up to 3% of patients with schizophrenia. 
In this study, out of a sample of 100 patients with psychotic disorders, 80 were investigated by 
array for the presence of CNVs. The assessment of the severity of psychiatric symptoms was 
performed using standardized instruments and ICD-10 was applied for diagnostic classification. 
In three patients, a submicroscopic CNV was demonstrated, one with a loss in 1q21.1 and two 
with a gain in 1p13.3 and 7q11.2, respectively. The association between these or other CNVs 
and schizophrenia or schizophrenia-like psychoses and their clinical implications still remain 
equivocal. While the CNV affected genes may enhance the vulnerability for psychiatric disorders 
via effects on neuronal architecture, these insights have not resulted in major changes in clinical 
practice as yet. Therefore, genome-wide array analysis should presently be restricted to those 
patients in whom psychotic symptoms are paired with other signs, particularly dysmorphisms 
and intellectual impairment.
Keywords: schizophrenia, psychotic disorders, microarray, copy number variants, 1q21, 
7q11.2, 1p13.3
Introduction
It has become obvious that the phenotypical presentation of psychotic disorders such 
as schizophrenia is extremely heterogeneous and that their symptoms may comprise 
the entire spectrum of psychopathology with high interindividual variation.1,2 Although 
the diagnostic boundaries of schizophrenia still remain unclear, the worldwide lifetime 
prevalence of this psychotic disorder is estimated to be 0.5%–1%.3 Previous studies 
have shown a heritability varying from 40%–70%,4 and a family history of schizo-
phrenia has been demonstrated to be the far most important risk factor.5,6 Over the past 
years, substantial evidence has emerged concerning the relevance of gene–environment 
interactions for the onset and course of schizophrenia.7,8
With the ongoing developments in genetic techniques, particularly array-based 
comparative genomic hybridization analysis, it has become possible to investigate 
the human genome in far greater detail than is possible with routine cytogenetic 
analysis, leading to the discovery of previously undetectable defects.9 These so-called 
copy number variants (CNVs) are deletions or duplications ranging in size from 
1 kb to 3 Mb resulting in loss or gain of a DNA segment. De novo microdeletions 
are generally considered of clinical significance and are frequently associated with 
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 intellectual disability.10 Of these patients, a substantial per-
centage develop symptoms from the affective and/or psychotic 
cluster after adolescence. Microdeletions and duplications 
may also be causatively involved in patients with normal 
intelligence and psychiatric disorders like schizophrenia11,12 
or autism.13,14 In his review, Kirov15 calculated a collective 
rate of 3% of patients with schizophrenia in whom rare dele-
tions in 1q42, 22q11, and 1q21 and duplications in 16p are 
found. In the general population, this percentage is estimated 
to be 0.1%–1%.16 The explanatory power of CNVs for the 
pathophysiology of psychiatric disorders in general and for 
their phenotypical presentation, however, still needs to be 
clarified.17,18
In the present study, genome-wide array analysis was 
performed in a group of patients with carefully diagnosed 
psychotic disorders in order to detect possible pathogenic 
CNVs. If present, their phenotypical relevance was explored 
and discussed.
Methods
Patients and assessments
Over a period of 30 months, 100 patients referred to the 
Vincent van Gogh Institute for Psychiatry for treatment of 
psychotic symptomatology were investigated. Patients with 
previously demonstrated cytogenetic aberrations and/or intel-
lectual disability (IQ , 70) were excluded. According to the 
medical ethical guidelines, 80 patients gave written informed 
consent and 20 refused further participation (CCMO registra-
tion number: NL20469.097.07). Assessment of symptoma-
tology and collection of data from history was performed 
using Comprehensive Assessment of Symptoms and History 
(CASH),19 Positive and Negative Syndrome Scale (PANSS),20 
and Clinical Global Impression Scale (CGI).21 Final clinical 
diagnoses were made in a so-called  Longitudinal Evaluation 
using All Data (LEAD) conference.22 Subsequently, patients 
were classified according to the International Statistical 
Classification of Disease and Related Health Problems, 
10th Revision (ICD-10) criteria.23 The main characteristics 
of the patients including the classification of their psychotic 
disorders are presented in Table 1. Pictures were taken of all 
patients for evaluation of dysmorphisms by an experienced 
clinical geneticist (IF). In case CNVs were found by array, the 
patient was examined in detail by the clinical geneticist.
Genetic analyses
DNA was isolated from an ethylenediaminetetraacetic acid 
(EDTA) blood sample and genome wide array analysis was 
performed with an average resolution of 200 kb using the 
Affymetrix 250 k SNP array platform (Affymetrix, Santa 
Clara, CA) as described previously.24
Results
As Table 1 shows, 50 patients fulfilled the criteria for schizo-
phrenia (F20) and in 11 patients, a diagnosis of acute and 
transient psychotic disorder was made (F23). A diagnosis 
of schizoaffective disorder (F25) was established in six 
patients whereas in another six, bipolar affective disorder, 
current episode manic with psychotic symptoms, was present 
(F31.2). In the remaining seven patients, various diagnoses 
were made (F29, n = 1; F28, n = 2; F22, n = 3; F21, n = 1). 
All patients received antipsychotic medication according to 
the hospital standards.
If screening for dysmorphic features suggested a par-
ticular monogenetic disorder, specific genetic tests were 
performed. However, no abnormalities were disclosed. 
In 77 patients, microarray analysis did not reveal any 
 abnormalities. In three patients, a submicroscopic chromo-
some imbalance was detected.
Patient A presented with a subacute onset of psychotic 
symptoms (total scores on PANSS and CGI-S were 79 and 
4, respectively) that remitted within 1 month after treatment 
with 2.5 mg haloperidol. Her history disclosed no major 
somatic or psychiatric diseases and there was no family 
load with neuropsychiatric or genetic disorders. In her, an 
interstitial loss of 3.5 Mb in 1q21.1 comprising 45 genes 
was found (Figure 1A). Patient B had a history of a mild 
and short-lasting psychotic episode 1 year before and did 
Table 1 Main characteristics of the patients (n = 80)
N %
Male/female 53/27 66/34
Mean age/range (years) 35.0/18–62
Mean age at onset of psychosis/range (years) 
Mean number of episodes/range
27.1/9–61 
2.8/1–15
Diagnoses (ICD-10)
Schizophrenia 
Schizoaffective disorder 
Acute and transient psychotic disorder 
Bipolar disorder (psychotic) 
Other psychotic disorders
50 
6 
11 
6 
7
62.5 
7.5 
13.8 
7.5 
8.8
PANSS scores (range) at inclusion
Total score 
Positive subscale 
Negative subscale 
Global subscale
86.1 (46–138) 
23.1 (11–37) 
19.9 (7–40) 
43.0 (22–67)
Mean CGI score (range) 
Severity
 
4.5 (2–7)
Abbreviations: PANSS, Positive and Negative Syndrome Scale; CGI, Clinical 
Global Impression Scale; ICD-10, International Statistical Classification of Disease 
and Related Health Problems, 10th Revision.
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Figure 1 In the upper panel (i) of each plot (A–C), the log2 test over reference ratio is plotted on the y-axis against the genomic Mb position from pter to qter on the 
respective chromosome represented by the idiogram on the x-axis in the lower part of each figure. 
Notes: Each red dot represents the average value for a certain SNP probe. The normal ratio with value 0 is indicated by the solid, horizontal blue line. Values for normal 
ratios range between -0.38 and +0.3. Values outside this range are considered abnormal.39 In panel (ii), the thick blue line represents the average of ten neighboring SNP 
probe values. In each figure, the aberrant chromosomal region is indicated by a rectangle that is enlarged in the lower left side of that figure. The gene content, 250 k SNP 
array probe coverage, structural variation and segmental duplications of the aberrant chromosomal region is shown in the lower right side of the figure (screen shot of the 
Human March 2006 (hg18) Assembly of the UCSC genome browser, http://genome.ucsc.edu/). In A, the interstitial 3.5 Mb loss in 1q21.1 of patient A is shown. In B, the 
interstitial gain in 1p13.3 (375 kb) detected in patient B is shown, and in C, the 1.1 Mb interstitial gain in 7q11.21q11.22 of patient C is shown.
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Table 2 Phenotype of the three patients with a potentially pathogenic CNV
Patient Psychiatric phenotype Somatic phenotype ICD-10 diagnosis CNV
A (61-year-old female) Pananxiety, religious delusions,  
delusions of influence, catastrophic  
thoughts, olfactory and auditory  
hallucinations
Dysplastic ear helices,  
length and head  
circumference  
,2.5 SD
Acute polymorphic psychotic  
disorder without symptoms  
of schizophrenia
3.5 Mb loss in 
1q21.1
B (36-year-old male) Pressure of speech, misrecognition  
of persons, thought incoherence,  
transient visual misinterpretations
No dysmorphisms Schizoaffective disorder,  
manic type
375 kb gain in 
1p13.3
C (22-year-old male) Delusions of persecution and  
grandiose identity, nonaffective  
verbal hallucinations about himself
No dysmorphisms Acute schizophrenia-like  
psychotic disorder
1.1 Mb gain in 
7q11.21q11.22
Abbreviations: CNV, copy number variant; ICD-10, International Statistical Classification of Disease and Related Health Problems, 10th Revision; SD, standard deviation.
not use any psychotropics. Apart from atypical psychotic 
symptoms, there were mild manic symptoms (total scores 
on PANSS and CGI-S were 78 and 5, respectively). With a 
treatment regimen comprising risperidone (4 mg daily) and 
lithium (1600 mg daily), all symptoms gradually resolved 
within 3 months. Here, a 375 kb interstitial gain in band 
p13 of chromosome 1 encompassing two genes was detected 
(Figure 1B). Patient C had neither a history of any psychi-
atric or somatic disease nor a family load with neuropsy-
chiatric or genetic disorders. Shortly prior to admission he 
developed paranoid psychotic symptoms (total scores on 
PANSS and CGI-S were 63 and 2, respectively) which fully 
remitted after 1 month of treatment with risperidone 4 mg 
daily. He had a 1.1 Mb interstitial gain in 7q11.21q11.22 
containing 11 genes (Figure 1C).
It remained unclear whether these CNVs had occurred 
de novo, since in none of the patients blood samples of 
the parents were available for carrier testing. A concise 
description of psychiatric and somatic phenotypes as well 
as ICD-10 classification is presented in Table 2.
Discussion
In three out of the 80 patients with psychotic disorders 
(3.75%), one loss and two gains . 250 kb were detected which 
is in accordance with the report by Kirov who calculated a 
collective percentage of 3% CNVs in schizophrenia.15
Apart from the recent report by Maiti et al,25 who found 
three de novo CNVs (two gains and one loss) in 7q11.21 in 
two families with monozygotic twins discordant for schizo-
phrenia in which, however, the breakpoints of these CNVs 
do not overlap with those in patient C, there is virtually no 
literature on the clinical significance. We recently detected a 
larger,  completely overlapping gain of 2.4 Mb in 7q11.21 in 
a  prenatal sample and the healthy father of this fetus with 
congenital diaphragmatic hernia. This makes it less likely 
that this gain is of clinical relevance.
With respect to 1p13.3, only Ohtsuki et al reported on 
a possible association with the netrin G1 (NTNG1) gene, 
located at 1p13.3, in Japanese families.26 This does not, 
however, apply to patient B, nor does it clarify his symptom 
profile. Its relevance is further challenged by the detection of 
an exactly similar gain in 1p13.3 (in addition to a pathogenic, 
de novo duplication in 10q) in an intellectually disabled 
patient without any psychiatric symptoms who inherited this 
gain from his healthy father (unpublished data).
Microdeletions in the 1q21 region have been reported 
in several genome-wide analyses in large populations.27,28 
A possible relationship between 1q21 and psychotic symp-
toms was reported by three research groups.29–31 Maiti et al 
reported on two de novo CNVs in families with monozygotic 
twins discordant for schizophrenia.25 Several genes are 
mapped on 1q21, such as the KCNN3,32 NOTCH2NL,25 and 
Connexin 40/50.33 Associations of these specific genes with 
schizophrenia in affected patients so far remain equivocal.
The results from this relatively small study using genome-
wide array analysis do not differ essentially from the reported 
large scale studies. It has to be stressed that the commonly 
applied diagnostic categories, derived from the ICD or Diag-
nostic and Statistical Manual of Mental Disorders systems, 
show no relationship to a specific genetic etiology. Moreover, 
a single gene defect never codes for a categorical psychiatric 
disorder, but may lead to a biological dysfunction that has a 
certain probability to be associated with the development of an 
array of psychiatric symptoms.14,17,18 This can best be illustrated 
by the discovery of the DISC1 gene in one family that was 
originally thought to be causally related to schizophrenia,34 
but later appeared to be involved in a biochemical cascade 
with consequences for neuronal functions predisposing for 
psychiatric symptoms across diagnostic boundaries.35,36
Although the CNVs detected in three out of 80 patients 
are not likely to be primarily involved in the evolution of their 
psychotic disorders, systematic genetic analysis in patients 
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may reveal novel recurrent microdeletion syndromes that, 
however, are nearly always accompanied with developmental 
delay and dysmorphisms, and do not seem to correlate with 
psychiatric symptoms.37,38 The counterpart microduplications 
in these regions often cause a much milder phenotype.
In conclusion, the results of this and other studies on the 
presence of CNVs in patients with psychotic disorders have 
not yet led to a further specification of their pathophysiology 
nor to breakthroughs in clinical strategies. Therefore, while 
genetic analysis should always be considered as part of the 
diagnostic equipment in neuropsychiatry, the application of 
genome-wide array analysis in patients with psychotic disor-
ders is mandatory only in the presence of other clinical signs 
such as facial dysmorphisms or developmental delay.
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